Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
Abstract
Background: The current guidelines of statins for primary cardiovascular disease (CVD) prevention were based on results from systematic reviews and meta‐analyses that suffer from limitations. Methods: We searched in PubMed for existing systematic reviews and individual open‐label or double‐blinded randomized controlled trials that compared a statin with a placebo or another, which were published in English until January 01, 2018. We performed a random‐effect pairwise meta‐analysis of all statins as a class and network meta‐analysis for the specific statins on different benefit and harm outcomes. Results: In the pairwise meta‐analyses, statins as a class showed statistically significant risk reductions on non‐fatal MI (risk ratio [RR] 0.62, 95% CI 0.53–0.72), CVD mortality (RR 0.80, 0.71–0.91), all‐cause mortality (RR 0.89, 0.85–0.93), non‐fatal stroke (RR 0.83, 0.75–0.92), unstable angina (RR 0.75, 0.63–0.91), and composite major cardiovascular events (RR 0.74, 0.67–0.81). Statins increased statistically significantly relative and absolute risks of myopathy (RR 1.08, 1.01–1.15; Risk difference [RD] 13, 2–24 per 10,000 person‐years); renal dysfunction (RR 1.12, 1.00–1.26; RD 16, 0–36 per 10,000 person‐years); and hepatic dysfunction (RR 1.16, 1.02–1.31; RD 8, 1–16 per 10,000 person‐years). The drug‐level network meta‐analyses showed that atorvastatin and rosuvastatin were most effective in reducing CVD events while atorvastatin appeared to have the best safety profile.…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.